Drug Trial Radar · NCT07357415
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
Last checked: Nov 20, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Jan 24, 2026
Primary completion
Oct 2028
Study completion Nov 2028
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Jan 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.
Conditions
- Obesity
- Overweight
Interventions
RetatrutideDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change from Baseline in Body WeightTime frame: Baseline, Week 104
Locations
35 sites in 3 countries. Site status is shown where the registry gives one.
Arizona Research Center
Phoenix, Arizona
Care Access - Huntington Beach
Huntington Beach, California
Los Angeles Institute for Metabolic Research
Los Angeles, California
New Horizon Research Center
Miami, Florida
Encore Medical Research - Weston
Weston, Florida
Pacific Diabetes & Endocrine Center
Honolulu, Hawaii
Monroe Biomedical Research - Louisville
Louisville, Kentucky
Brigham and Women's Hospital Diabetes Program
Boston, Massachusetts
Great Lakes Research Group, Inc.
Bay City, Michigan
NYC Research INC
Long Island City, New York
Weill Cornell Medical College
New York, New York
Care Access - Raleigh
Raleigh, North Carolina
New Phase Research and Development
Knoxville, Tennessee
Velocity Clinical Research, Dallas
Dallas, Texas
Cedar Health Research - Texas Native Health
Dallas, Texas
Cedar Health Research
Dallas, Texas
Cedar Health Research - Fort Worth
Fort Worth, Texas
Advanced Research Institute
Ogden, Utah
Dominion Medical Associates, Inc.
Richmond, Virginia
CAMC Institute for Academic Medicine
Charleston, West Virginia
Cicemo Srl
Buenos Aires, Argentina
CARDIAMET Investigaciones Médicas
Buenos Aires, Argentina
Stat Research S.A.
Buenos Aires, Argentina
Centro de Investigaciones Metabólicas (CINME)
Buenos Aires, Argentina
Centro Médico Viamonte
Buenos Aires, Argentina
Aggarwal and Associates Limited
Brampton, Canada
Med Trust Research
Courtice, Canada
Winterberry Research Inc.
Hamilton, Canada
Diex Recherche Inc. Division Joliette
Joliette, Canada
Milestone Research Inc.
London, Canada
Diex Recherche Inc. Division Quebec
Québec, Canada
Diex Recherche Inc. Division Sherbrooke
Sherbrooke, Canada
Canadian Phase Onward
Toronto, Canada
Dr. Anil K. Gupta Medicine Professional Corporation
Toronto, Canada
C.I.C. Mauricie inc.
Trois-Rivières, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.